Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bronchopulmonary Dysplasia

ClinicalTrials.gov lists 358 trials for Bronchopulmonary Dysplasia or a narrower condition beneath it. NICHD Neonatal Research Network has the most among industry and government lead sponsors, with 14.

MeSH D001997 Respiratory Tract Diseases C08 C16 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 26 Phase 1/2 Phase 1/2 17 Phase 2 Phase 2 39 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 34 Phase 4 Phase 4 18 Not applicable Not applicable 107 Observational Observational 106 Phase 1 Phase 1 26 Phase 1/2 Phase 1/2 17 Phase 2 Phase 2 39 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 34 Phase 4 Phase 4 18 Not applicable Not applicable 107 Observational Observational 106

Trials per phase

358 of the 358 trials are tagged with Bronchopulmonary Dysplasia itself; the rest are tagged with a narrower condition beneath it.

Get the Bronchopulmonary Dysplasia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bronchopulmonary Dysplasia trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 29

1991: 2 trials (Not applicable 1, Phase 2/3 1) 1992: 1 trials (Phase 3 1) 1993: 2 trials (Observational 1, Phase 3 1) 1995: 1 trials (Phase 3 1) 1996: 4 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1/2 1) 1998: 1 trials (Phase 3 1) 2000: 3 trials (Phase 3 2, Phase 1/2 1) 2001: 3 trials (Not applicable 2, Phase 3 1) 2002: 3 trials (Observational 2, Phase 1/2 1) 2003: 1 trials (Phase 1 1) 2004: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1) 2005: 6 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 2) 2006: 6 trials (Observational 2, Phase 3 1, Phase 2/3 1, Phase 2 2) 2007: 9 trials (Observational 2, Not applicable 3, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 2008: 6 trials (Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1 1) 2009: 6 trials (Observational 1, Phase 4 3, Phase 3 1, Phase 2/3 1) 2010: 11 trials (Observational 2, Phase 4 1, Phase 3 2, Phase 2 3, Phase 1 3) 2011: 14 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 2) 2012: 10 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 1, Phase 2/3 2) 2013: 11 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 2/3 1, Phase 2 3) 2014: 12 trials (Observational 2, Not applicable 8, Phase 2 1, Phase 1 1) 2015: 9 trials (Observational 1, Not applicable 4, Phase 3 2, Phase 2 1, Phase 1/2 1) 2016: 11 trials (Observational 4, Not applicable 4, Phase 3 1, Phase 1/2 2) 2017: 16 trials (Observational 3, Not applicable 7, Phase 4 1, Phase 2/3 1, Phase 2 2, Phase 1 2) 2018: 26 trials (Observational 6, Not applicable 10, Phase 4 1, Phase 2 5, Phase 1 4) 2019: 29 trials (Observational 8, Not applicable 5, Phase 4 3, Phase 3 1, Phase 2 4, Phase 1/2 4, Phase 1 4) 2020: 24 trials (Observational 15, Not applicable 8, Phase 3 1) 2021: 22 trials (Observational 6, Not applicable 8, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1 1) 2022: 18 trials (Observational 5, Not applicable 8, Phase 4 1, Phase 3 1, Phase 1/2 1, Phase 1 2) 2023: 20 trials (Observational 7, Not applicable 10, Phase 4 1, Phase 2/3 1, Phase 1/2 1) 2024: 20 trials (Observational 7, Not applicable 6, Phase 4 2, Phase 3 1, Phase 2 1, Phase 1/2 2, Phase 1 1) 2025: 17 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 2/3 1, Phase 2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 23
2025 17
2024 20
2023 20
2022 18
2021 22
2020 24
2019 29
2018 26
2017 16

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 23 trials starting in 2026 and about 21 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 39 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 198 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bronchopulmonary Dysplasia trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 26
Phase 1/2 17
Phase 2 39
Phase 2/3 11
Phase 3 34
Phase 4 18
Not applicable 107
Observational 106

How many Bronchopulmonary Dysplasia trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 22
Recruiting 44
Enrolling by invitation 1
Active, not recruiting 12
Completed 180

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bronchopulmonary Dysplasia trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
NICHD Neonatal Research Network 14
Medipost Co Ltd. 6
National Heart, Lung, and Blood Institute (NHLBI) 5
National Center for Research Resources (NCRR) 4

Which drugs are being tested for Bronchopulmonary Dysplasia? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
L-Citrulline 3
Calfactant 3

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
PNEUMOSTEM 6
citrate of caffeine 6
1% Azithromycin 6
Budesonide EC 6
Inhaled Nitric Oxide (iNO) use 5

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bronchopulmonary Dysplasia trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Patent Ductus Aretriosus 631 1
Death 295 3
Respiratory Deterioration up to 24 hours post-transfusion 178 1
Necrotizing enterocolitis 167 3
Intraventricular hemorrhage (IVH) Grade 3 or 4 164 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bronchopulmonary Dysplasia? (544)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Bronchopulmonary dysplasia to predict neurodevelopmental impairment in infants born extremely preterm. Pediatric research 2025 Yes
Association of a Count of Inpatient Morbidities with 2-Year Outcomes among Infants Born Extremely Preterm. The Journal of pediatrics 2025 Yes
Inhaled Nitric Oxide Treatment of Early Pulmonary Hypertension to Reduce the Risk of Death or Bronchopulmonary Dysplasia in Infants Born Extremely Preterm: A Masked Randomized Controlled Trial. The Journal of pediatrics 2025 Yes
Daily participation in preterm-born children: An exploratory and comparative study. Early human development 2025 Yes
Patent Ductus Arteriosus, Hydrocortisone, and Outcome among Infants Born Extremely Preterm: Secondary Analysis of the Hydrocortisone Trial. The Journal of pediatrics 2025 Yes

Showing 5 of 544 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Bronchopulmonary dysplasia Point prevalence 1-5 / 10 000 Europe Not stated Exact
Bronchopulmonary dysplasia Point prevalence 1-5 / 10 000 Europe Not stated Exact
Bronchopulmonary dysplasia Point prevalence 1-5 / 10 000 Europe Not stated Unspecified

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Bronchopulmonary dysplasia 70589 Exact Orphanet Rare Disease Ontology (ORDO)
Bronchopulmonary dysplasia 70589 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages